Abstract
The potential benefits of transplantation were already recognized in 1968, as reflected in the statement from the Bethesda conference chaired by Francis Moore[1]: ‘Cardiac transplantation, still in an early stage of development, shows promise for the future treatment of many people with severe heart disease.’ At that time there were 20 survivors of 50 heart transplant procedures. Since then, cardiac transplantation has evolved from an experimental to an accepted clinical procedure, endorsed by Medicare in 1986 as ‘best therapy’ for end-stage heart failure. The current survival rate is 80-85% at I year and 60-70% at 5 years[2]. There have been over 30 000 heart transplants performed in the world, involving over 250 heart transplant centers.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Moore FD (Chairman). Fifth Bethesda Conference Report: Cardiac and other organ transplantation. Am J Cardiol. 1968;22:896.
Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: Eleventh official report, 1994. J Heart Lung Transplant. 1994;13:561.
Bach DS, Bolling SF. Early improvement in congestive heart failure after correction of secondary mitral regurgitation in end-stage cardiomyopathy. Am Heart J. 1995;129:1165.
Louie HW, Laks H, Milgalter E et al. Ischemic cardiomyopathy: criteria for coronary revascularization and cardiac transplantation. Circulation. 1991(Suppl. III):290.
Elefteriades JA, Tolis G, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411.
Cohn JN, Johnson G, Zicsche S et al. A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.
The SOLVD Investigators: effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685.
Fonarow GC, Chelimsky-Fallick C. Stevenson LW et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842.
Miller LW, Kubo SH, Young JB et al. Report of the consensus conference on candidate selection for cardiac transplantation. J Heart Lung Transplant. 1995;14:562.
Votapka TV, Pennington DG. Circulatory assist devices in congestive heart failure. Cardiol Clin. 1994;12:143.
Frazier OH, Rose EA, Macmanus Q et al. Multicenter clinical evaluation of the HeartMate 1000IP left ventricular assist device. Ann Thorac Surg. 1992;53:1080.
Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol. 1994;23:553.
Semigran MJ, Thaik CM, Fifer MA et al. Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:462.
O’Connell JB, Constanzo-Nordin MR, Subramanian R et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic, and prognostic characteristics. J Am Coll Cardiol. 1986;8:52.
Regan TJ. Alcohol and the cardiovascular system: a review. J Am Med Assoc. 1991;264:377.
Packer DL, Bardy GH, Worley SJ et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563.
Grogan M, Smith HC, Gersh BJ, Wood DW. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69:1570.
Middlekauff HR, Weiner I. Stevenson WG, Saxon LA, Stevenson LW. Lou dose amiodarone for atrial fibrillation in advanced heart failure restores sinus rhythm and improves functional capacity. Circulation. 1992;86:1–808.
Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis. 1985;27:325.
Stevenson LW. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant. 1991;10:468.
Stevenson LW, Perloff JK. The limited reliability of physical signs for the estimation of hemodynamics in chronic heart failure. J Am Med Assoc. 1989;261:884.
Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in dilated heart failure. Circulation. 1986;74:1303.
Stevenson LW, Brunken RC, Belil D et al. Afterload reduction with vasodilators and diaretics decreases mitral valve regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol. 1990;15:174.
Mudge GH, Goldstein S, Addonizio LJ et al. Task force 3: recipient guidelines/ prioritization. J Am Cull Cardiol. 1993;22:21.
Steimle AE, Slevenson LW, Chelimsky-Fallick C, Fonarow GA, Tillisch JH. Prolonged maintenance of cardiac output with normal filling pressures during chronic therapy for advanced heart failure. Circulation. 1993;88:1–59A.
Hamilton MA, Stevenson LW, Child JS et al. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated cardiomyopathy. Am J Cardiol. 1991;67:259.
Fonarow GC. Stevenson LW, Walden JA et al. Impact of a comprehensive management program on the hospitalization rate for patients with advanced heart failure (ACC abstract ref. 1995).
Waagstein F, Caidahl K. Wallentin I, Bergh C-H. Hjalmarson A. Long-term betablockade in congestive cardiomyopathy: effects of short and long-term metoprolol treatment followed by withdrawal and readmission of metoprolol. Circulation. 1989;80:551.
Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1442.
Erlebacher JA, Bhardwaj M, Suresh A, Leber GB, Goldweit RS. Beta-blocker treatment of idiopathic and ischemic dilated cardiomyopathy in patients with ejection fractions-20%. Am J Cardiol. 1993;71:1467.
Hamer AWF, Arkles LB, Johns JA. Benelicial effects of low dose amiodarone in patients with congestive heart failure: a placebo-controlled trial. J Am Coll Cardiol. 1989;14:1768.
Doval HC, Nul DR, Grancello et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493.
Singh SN, Fletcher RD, Fisehr SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77.
Wilson JR, Schwartz JS, St. John Sutton M et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular eclopic activity. J Am Coll Cardiol. 1983;2:403.
DiSalvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143.
Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257.
Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819.
Steimle AE, Stevenson LW, Hamilton MA, Fonarow GA. Prediction of spontaneous improvement in recent onset cardiomyopathy after referral for transplantation. Circulation. 1993;88:1–93A.
Stevenson LW. Fonarow G, Hamilton M, Tillisch JH. Why cardiac output is not a good hemodynamic target for therapy in advanced heart failure. Circulation. 1994;90:1–611.
Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patient with advanced left ventricular dysfunction. Circulation. 1993;88:2953.
O’Connell JB, Gunnar RM, Evans RW, Fricker FJ et al. Task force 1: organization of heart transplantation in the U.S. J Am Coll Cardiol. 1993;22:8.
Keogh AM, Freund J, Baron DW, Hickie JB. Timing of transplantation in idiopathic dilated cardiomyopathy. Am J Cardiol. 1988;61:418.
Stevenson LW, Couper G, Natterson BJ et al. Target heart failure population for new therapies. Circulation. 1995 (In press).
Lee TH, Hamilton MA, Stevenson LW et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72:672.
Cohn J, Johnson G, Shabetai R et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87(Suppl.VI):VI5.
Szlachic J, Massie B, Kramer B, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 1985;55:1037.
Likoff M, Chandler S, Kay H. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or ischemic caridomyopathy. Am J Cardiol. 1987:59:634.
Mancini DM, Eisen H, Kussmaul W et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778.
Haywood GA, Rickenbacher PR, Trindade PT et al. Deaths in patients awaiting heart transplantation: the need to identify high risk category two patients. Circulation. 1994;90:1–360.
Stevenson LW, Steimle AE, Chelimsky-Fallick C et al. Outcomes predicted by peak oxygen consumption during evaluation of 333 patients with advanced heart failure. Circulation. 1993;88:1–94A.
Stevenson LW, Steimle AB, Fonarow G et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol. 1995;25:163.
Stevenson LW, Sietsema K, Tillisch JH et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation. 1990;81:78.
Walden JA, Stevenson LW, Dracup K et al. Extended comparison of quality of life between stable heart failure patient and heart transplant recipients. J Heart Lung Transplant. 1994;13:1109.
Stevenson LW, Miller L. Cardiac transplantation as therapy for heart failure. Curr Prob Cardiol. 1991;16:219.
Olivari MT, Antolick A, Kaye MP, Jamieson SW, Ring WS. Heart transplantation in elderly patients. J Heart Transplant. 1988;7:258.
Grattan MT, Moreno-Cabral CE, Starnes VA et al. Eight-year results of cyclosporintreated patients with cardiac transplants. J Thorac Cardiovasc Surg. 1990;99:500.
Kaye MP. Registry of the International Society for Heart and Lung Transplantation: Tenth official report-1993. J Heart Lung Transplant. 1993;12:541.
Hosenpud JD, DeMarco T, Frazier H et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation. 1991;84:111–338.
Stolf NAG, Higushi L, Bocchi E et al. Heart transplantation in patients with Chagas’ disease cardiomyopathy. J Heart Transplant. 1987;5:307.
Copeland JG, Emery RW, Levinson MM et al. Selection of patients for cardiac transplantation. Circulation. 1987;75:2.
Olbrisch ME, Levenson JL. Psychological evaluation of heart transplantation candidates: an international survey of process, criteria and outcomes. J Heart Lung Transplant. 1991;10:948.
Rodriguez MD, Colon A, Santiago-Delphin EA. Psychosocial profile of non-compliant patients. Transplant Proc. 1991;23:1807.
Herrick CM, Mealey PC, Tischner LL. Holland CS. Combined heart failure-transplant program: advantages in assessing medical compliance. J Heart Transplant. 1987;6:141.
Penn I. Cancers after cyclosporin therapy. Transplant Proc. 1988;20:276.
Erickson KW, Costanzo-Nordin MR, O’Sullivan EJ et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant. 1990;9:526.
Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48.
Kaye MP. The Registry of the International Society for Heart and Lung Transplantation, Ninth official report. J Heart Lung Transplant. 1992;599:11.
Desruennes M, Muneretto C, Gandjbakhch 1 et al. Heterotopic heart transplantation: current status in 1988. J Heart Transplant. 1989;8:479.
Wright RS, Levine MS, Bellamy PE et al. Ventilatory and diffusion abnormalities in potential heart-transplant recipients. Chest. 1990;98:816.
Radovancevic B, Poindexter S, Birovljev S et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg. 1990;4:309.
Myers BD, Peterson C, Molina C et al. Role of cardiac atria in the human renal response to changing plasma volume. Am J Physiol. 1988;254:F562.
Wei CM, Kao PC, Lin JT, Heublein DM, Schaff HV, Burnett JC Jr: Circulating β atrial natriuretic factor in congestive heart failure. Circulation. 1993;88:1016.
Bourge RC, Naftal DC, Costanzo M et al. Risk factors for death after cardiac transplantation: a multi-institutional study. J Heart Lung Transplant. 1993;12:549.
Laffel GL, Barnett Al, Finkelstein S et al. The relation between experience and outcome in heart transplantation. N Engl J Med. 1992;327:1220.
Flaker GC, Blackshear JL, McBride R et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20:527.
Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J. 1995;129:564.
Konstam MA, Dracup K, Baker DW et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Rockvillc, M: US Dept. of Health and Human Services; 1994.
Chelimsky-Fallick C, Middlekauff HR, Stevenson WG et al. Amiodarone therapy does not compromise subsequent heart transplantation. J Am Coll Cardiol. 1992;20:1556.
Stevenson LW, Warner SL, Steimle AE et al. The impending crisis awaiting cardiac transplantation: modeling a solution based on selection. Circulation. 1994;89:450.
Norman JC, Colley DA, Igo SR et al. Prognostic indices for survival during postcardiotomy intra-aorlic balloon pumping. J Thorac Cardiovasc Surg. 1977;74:709.
Loisance DY, Deleuze PH, Houel K et al. Pharmacologic bridge to cardiac transplantation: current limitations. Ann Thorac Surg. 1993;55:310.
McCarthy PM, Sabik JF. Implantable circulatory support devices as a bridge to heart transplantation. Semin Thorac Cardiovasc Surg. 1994;6:174.
Evans RW. Executive summary: The National Cooperative Transplantation Study. Report BHARC-100-91-020. Seattle: Battelle Seattle Research Center, June 1991.
Pfeffer MA, Braunwald E, Moye LA et al. (on behalf of the SAVE investigators). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669.
The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293
CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative New Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429.
Stevenson LW, Role of exercise in the evaluation of candidates for cardiac transplantation: In: Wasserman K, editor. Exercise gas exchange in heart disease. New York: Futura; 1995 (In press).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Stevenson, L.W. (1996). Selection and Management of the Potential Candidate for Cardiac Transplantation. In: Cooper, D.K.C., Miller, L.W., Patterson, G.A. (eds) The Transplantation and Replacement of Thoracic Organs. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-34287-0_19
Download citation
DOI: https://doi.org/10.1007/978-0-585-34287-0_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-8898-2
Online ISBN: 978-0-585-34287-0
eBook Packages: Springer Book Archive